Genvoya

EVG/COBI/FTC/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

Recommended initial regimen in certain clinical situations
Single-Tablet Regimen

Standard Dose

One tablet once daily with food. For people taking HIV treatment for the first time (treatment-naïve) or individuals with a suppressed viral load on a stable HIV regimen for at least 6 months who have no known resistance to the elvitegravir, emtricitabine, or tenofovir components of the regimen. The tablet contains 150 mg of the INSTI elvitegravir boosted by 150 mg cobicistat plus 200 mg emtricitabine and 10 mg tenofovir alafenamide (TAF).

For adults and children weighing at least 55 pounds (25 kg) and having a creatinine clearance of at least 30 mL/min (measurement of kidney function), as well as adults with creatinine clearance below 15 mL/min who are receiving chronic hemodialysis (HD). For those on HD, take a tablet once daily and administer after completion of hemodialysis on days of HD treatment.

Take the missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. The dose cannot be adjusted for people with liver problems. Genvoya is not recommended for people who have severe liver problems, a CrCl between 15 to 30 mL/min, or a CrCl less than 15 mL/min who are not receiving chronic hemodialysis.

See the individual drugs contained in Genvoya: Emtriva and Tybost (elvitegravir is not available separately, and neither is TAF for use in HIV, but see Descovy).

See package insert for more complete information on potential side effects and interactions.

Manufacturer

Gilead Sciences, Inc.
gilead.com; genvoya.com
(800) GILEAD-5 (445-3235)

AWP

$3,885.97/month in certain clinical situations

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments